Related Issuers
by Stephen Carter
Mar 28, 2025 11:35 AM ET
Opal Bidco SAS/Opal US LLC (Opella) (OPALBD) EUR2.25bn equivalent (up from EUR2bn equivalent) 144A/Reg S sr sec notes 2-part. B1/B+/BB- (stable/stable/stable). GS (EUR)/MS (US$) physical books/BNPP/Citi/GS/MS/Barc/HSBC/SocGen jt glocos/BofA/RBC/Santander/UBS/DB/MUFG/Nomura/CA/ING/Mizuho/Natixis/WFS/DB/Commerz/SMBC Nikko jt books. No reg rights. List ISE. NY law.
- EUR1.25bn (from EUR1bn minimum) sr sec notes due 2032 (7y). NC3 (50%,25%par). IPT: low 6s. Revised IPT: high 5s.
- US$ (EUR1bn equivalent) (unchanged) sr sec notes due 2032 (7y). NC3 (50%,25%par). IPT: low 7s. Revised IPT: high 6s.
Roadshow: London 03/24-25, NY 03/26-27, virtual 03/28. Official price talk and books close on 03/31 (Books were closing US$ 5pm NYT 03/31, EUR 12pm UKT 04/01). UOP: along with EUR5.2bn (down from EUR5.45bn equivalent) (EUR1.75bn and US$ (EUR3.45bn equivalent)) sr sec term loan B (and EUR1.2bn revolver), to fund the purchase of a 50% controlling stake in Sanofi's consumer health division Opella by CD&R (Bpifrance will purchase a 2% interest and Sanofi will remain a 48% minority shareholder. Management will own less than 1%). CD&R will contribute EUR1.208bn equity-like sub PIK notes. Total equity contributions fo $6.750bn. Enterprise value of EUR16bn. Closing is expected in Q2 2025 at the earliest. Biz: consumer healthcare products, including a portfolio of iconic brands, such as Allegra, Doliprane, and Dulcolex, as well as over-the-counter vitamins and minerals. HQ: Paris, France. (Acquisition announced 10/21/2024).
Global investor presentation: Europe 9am UKT 03/26 at The Landmark Hotel https://evercall.co/oacc/26199; US 9am NYT 03/26 at the Pendry Manhattan West https://www.netroadshow.com/events/login?show=84d62d24&confId=79907.
Deal Roadshow: https://urldefense.com/v3/__https:/dealroadshow.com/e/OPELLA25__;!!O2kDR7mm-zSJ!u8Wp-2nnr_J5VfcVml8cyMbhOhPbUB0heqCjsJIjHXa3KTr2_Rrki3cwTOANafSt-ii5cEfKNJ-E31qm0cQCkPQ$. Entry code: OPELA25.